Fortress Biotech, Inc. (NASDAQ:FBIO) Files An 8-K Submission of Matters to a Vote of Security Holders

Fortress Biotech, Inc. (NASDAQ:FBIO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.

The 2019 annual meeting of stockholders of Fortress Biotech, Inc. (“Fortress” or “the Company”) was held on June 18, 2019. The following matters were voted on by the stockholders: (i) the election of seven directors; (ii) the ratification of the appointment of BDO USA, LLP as Fortress’s independent registered public accounting firm for the year ending December 31, 2019; (iii) an advisory vote to approve the compensation of the Company’s named executive officers; and (iv) an advisory vote on the frequency of the advisory vote to approve the compensation of the Company’s named executive officers.

Item 1: Election of directors:

6,043,351 4,901,988 21,072,104 87,866


About Fortress Biotech, Inc. (NASDAQ:FBIO)

Story continues below

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

An ad to help with our costs